NFKB1 and B-cell chronic lymphocytic leukemia: Preclinical trials demonstrated that ibrutinib promotes apoptosis of CLL cells, inhibits activation of phosphatidylinositol‐3 kinase (PI3K), ERK1, and NF‐κB by external microenvironment signals, and also prevents CLL proliferation.6